Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro
Authors:
Open Access
- 16 February 2022
- journal article
- research article
- Published by Springer Nature in Odontology
- Vol. 110 (4) , 634-647
Abstract
Antiangiogenic medications target the de novo blood vessel formation in tumorigenesis. However, these novel drugs have been linked to the onset of medication-related osteonecrosis of the jaw (MRONJ). The aim of this in vitro study was to examine the effects of the vascular endothelial growth factor A (VEGFA) antibody bevacizumab (BEV) and the receptor tyrosine kinase inhibitor (RTKI) sunitinib (SUN) on primary human osteoblasts derived from the alveolar bone. Primary human alveolar osteoblasts (HAOBs) were treated with BEV or SUN for 48 h. Cellular metabolic activity was examined by XTT assay. Differentially regulated genes were identified by screening of 22 selected osteogenic and angiogenic markers by quantitative real-time reverse transcriptase polymerase chain reaction (qRT2-PCR). Protein levels of alkaline phosphatase (ALP), collagen type 1, α1 (COL1A1) and secreted protein acidic and cysteine rich (SPARC) were examined by enzyme-linked immunoassay (ELISA). Treatment with BEV and SUN did not exhibit direct cytotoxic effects in HAOBs as confirmed by XTT assay. Of the 22 genes examined by qRT2-PCR, four genes were significantly regulated after BEV treatment and eight genes in the SUN group as compared to the control group. Gene expression levels of ALPL, COL1A1 and SPARC were significantly downregulated by both drugs. Further analysis by ELISA indicated the downregulation of protein levels of ALP, COL1A1 and SPARC in the BEV and SUN groups. The effects of BEV and SUN in HAOBs may be mediated by alterations to osteogenic and catabolic markers. Therapeutic or preventive strategies in MRONJ may address drug-induced depression of osteoblast differentiation.Keywords
Funding Information
- Universitätsklinikum Bonn
This publication has 81 references indexed in Scilit:
- Effects of Pamidronate on Human Alveolar Osteoblasts In VitroJournal of Oral and Maxillofacial Surgery, 2012
- Osteonecrosis of the Jaw and the Role of MacrophagesJNCI: Journal of the National Cancer Institute, 2010
- Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancerBreast Cancer Research and Treatment, 2010
- Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell CarcinomaCancer Research, 2010
- Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPPBritish Journal of Haematology, 2008
- Inhibition of Oral Mucosal Cell Wound Healing by BisphosphonatesJournal of Oral and Maxillofacial Surgery, 2008
- Osteoclasts: What Do They Do and How Do They Do It?The American Journal of Pathology, 2007
- Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell CarcinomaThe Oncologist, 2007
- Differential Protein Profiling of Primary versus Immortalized Human RPE Cells Identifies Expression Patterns Associated with Cytoskeletal Remodeling and Cell SurvivalJournal of Proteome Research, 2006
- Vascular endothelial growth factor receptors in osteoclast differentiation and functionBiochemical and Biophysical Research Communications, 2005